Background: Large-scale validation of a non-invasive combined radiomics-clinic (CoRC) model for assessing fibrosis and necroinflammation remains lacking. We aimed to develop and validate a CoRC model based on conventional MRI for diagnosing clinically significant liver fibrosis (≥ F2) and necroinflammation (≥ G2). Methods: This retrospective cohort study recruited 537 patients with pathologically proven liver fibrosis and necroinflammation at center 1 from May 2015 to Aug 2020 and center 2 between Jan 2011 and Jan 2021. 394 patients were randomly allocated into training (n = 276) and internal test (n = 118) cohorts at center 1. A temporal test cohort at center 1 (n = 96) and an external test cohort from center 2 (n = 47) were used for validation. Automated entire liver segmentation used ResUNet-based Human-in-the-Loop approach. Radiomics features were extracted from the mask on fat-suppressed T2-weighted and delayed enhanced T1-weighted images separately. Radiomics signatures were generated using logistic regression. Radiomics-scores and optimal clinical biomarkers as independent risk factors were integrated into the CoRC models in the training cohort with multivariate logistic regression. Models were tested in independent cohorts. Model performances were mainly evaluated with the area under the receiver operating characteristic curves (AUCs). Findings: In the internal, temporal, and external test cohorts, CoRC model 1 yielded AUCs of 0.79 (95% CI: 0.70, 0.86), 0.82 (95% CI: 0.73, 0.89), and 0.83 (95% CI: 0.69, 0.92) for ≥ F2, meanwhile, CoRC model 2 showed AUCs of 0.86 (95% CI: 0.79, 0.92), 0.79 (95% CI: 0.68, 0.86), and 0.89 (95% CI: 0.76, 0.96) for ≥ G2. In internal/temporal test transient elastography-based liver stiffness measurement (TE-LSM) subgroups, we compared the performance of CoRC models with TE-LSM (AUC 0.78 vs.0.79, P = 0.86 / 0.82 vs. 0.73, P = 0.14 for ≥ F2, whereas 0.88 vs. 0.81, P = 0.16 / 0.79 vs. 0.74, P = 0.49 for ≥ G2). Interpretation: CoRC models exhibited promising diagnostic performances for clinically significant liver fibrosis and necroinflammation, which could be a potential alternative when TE-LSM is unavailable. Funding: This research was supported by the National Key R&D Program of China (2021YFF0501504); the National Natural Science Foundation of China (NSFC, No. 81830053, 92059202, and 61821002); the Key Research and Development Program of Jiangsu Province (BE2020717) Declaration of Interest: Yang Song is from a commercial company, Siemens Healthineers Ltd., as a MR Scientific Specialist doing technical support in this study under Siemens collaboration regulation without any payment and personal concern regarding to this study. Our study did not use any commercial product from Siemens. Neither this manuscript, in its entirety, nor any part thereof, has been submitted for publication elsewhere. All authors have no conflicts of interest to disclose Ethical Approval: This retrospective multi-center study was approved by the institutional ethics committee of all participating centers, which waived the requirement for written informed consent. All patient data were anonymized before analysis.